Clinical Trials · NCT00595140

Acute Application of Pegvisomant and Octreotide in Acromegaly

CompletedPhase 4Octreotide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
Ludwig-Maximilians - University of Munich
Enrollment
10
Start date
Jan 2008
Locations
1 site, Germany
Primary endpoint
The decrease of endogenous growth hormone
View Octreotide compound reference